🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Pancreatic Ductal Adenocarcinoma

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma NCT06261359Phase 21 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: CEND-1, Gemcitabine, Nab paclitaxel Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC NCT07145450Phase 1, Phase 210 sites📍 Copenhagen📍 Berlin📍 Dresden Anocca AB · Tests: ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-002 (TCR-T cells targeting … Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer NCT06984562NA1 site📍 Philadelphia Fox Chase Cancer Center · Tests: Adaptive Radiation Therapy Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma NCT05919238Phase 13 sites📍 Duarte📍 Irvine📍 Ramat Gan Impact Biotech Ltd · Tests: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328Phase 3333 sites📍 Gilbert📍 Gilbert📍 Peoria NRG Oncology · Tests: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 120 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620NA1 site📍 Vancouver British Columbia Cancer Agency · Tests: Genetic testing, Optional biopsy, Tissue collection Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05688215Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer NCT06850623Phase 210 sites📍 Scottsdale📍 Stanford📍 Boston EXACT Therapeutics AS · Tests: Acoustic Cluster Therapy, Modified FOLFIRINOX OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT07089940EARLY Phase 11 site📍 Portland OHSU Knight Cancer Institute · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103 A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer NCT07101679Phase 21 site📍 Chengdu West China Hospital · Tests: LICSBR NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NCT07595172Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: NALIRIFOX+Adebrelimab, PULSAR NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer NCT05257993Phase 1, Phase 24 sites📍 Gyeonggi-do📍 Seoul📍 Seoul Onconic Therapeutics Inc. · Tests: JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer NCT07645651Phase 11 site📍 Seattle University of Washington · Tests: Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. NCT07157033Phase 1, Phase 25 sites📍 Duarte📍 Irvine📍 Detroit Xerient Pharma · Tests: XER-001 AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 PULSAR in Systemic Therapy for Pancreatic Cancer NCT07269626Phase 21 site📍 Seoul Samsung Medical Center · Tests: Personalized Ultrafractionated Adaptive Radiotherapy Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer NCT06600906n/a1 site📍 San Francisco University of California, San Francisco · Tests: Hyperpolarized 13C-Pyruvate, Computed tomography (CT), Magnetic Resonance Imaging (MRI) The KN510713 Study in Combination With mFOLFIRINOX NCT07114861Phase 1, Phase 21 site📍 Goyang-si New Cancer Cure-Bio Co.,Ltd. · Tests: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX, Study drug: KN510 120mg/day + KN71… Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site📍 Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Drug: IBI3028 A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy NCT07235202Phase 1, Phase 24 sites📍 Beijing📍 Guangzhou📍 Harbin Shenzhen Majory Biotechnology Co., Ltd. · Tests: MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel, Gemcitabine (GEM) Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690EARLY Phase 11 site📍 Portland OHSU Knight Cancer Institute · Tests: Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC NCT07155850NA2 sites📍 Roma📍 London BetaGlue Therapeutics SpA · Tests: Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma NCT07480928Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodep… Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma NCT06831136Phase 21 site📍 Houston The University of Texas Health Science Center, Houston · Tests: Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablati… A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187Phase 110 sites📍 Denver📍 Orlando📍 Sarasota Dren Bio · Tests: DR-0202 AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer NCT07619313Phase 11 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy